The matrikine tenascin-C protects multipotential stromal cells/mesenchymal stem cells from death cytokines such as FasL

Tissue Engineering - Part A

Volumn 19, Issue 17-18, 2013, Pages 1972-1983

  Rodrigues, Melanie ^a   Yates, Cecelia C ^a,b   Nuschke, Austin ^a,b   Griffith, Linda ^c   Wells, Alan ^a,b,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MEMBRANES; FLOWCHARTING; LIGANDS; REPAIR; STEM CELLS;

EGFR SIGNALING; EPIDERMAL GROWTH FACTOR RECEPTORS; EXTRACELLULAR MATRICES; FOREIGN BODIES; MATRIX COMPONENTS; NATURALLY OCCURRING; SERUM DEPRIVATION; STROMAL CELLS;

CELL CULTURE;

COLLAGEN TYPE 1; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS LIGAND; FIBRONECTIN; INTEGRIN; OXYGEN; TENASCIN;

ARTICLE; BINDING AFFINITY; CELL GROWTH; CELL MEMBRANE; CELL PROTECTION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IMPLANTATION; IN VITRO STUDY; LIGAND BINDING; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; SERUM; SIGNAL TRANSDUCTION; STROMA CELL; SURVIVAL; UPREGULATION; WOUND HEALING; APOPTOSIS; CELL ADHESION; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CYTOLOGY; DRUG EFFECT; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; MESENCHYMAL STROMA CELL; METABOLISM; MULTIPOTENT STEM CELL; DRUG EFFECTS;

APOPTOSIS; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; FAS LIGAND PROTEIN; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MESENCHYMAL STROMAL CELLS; MULTIPOTENT STEM CELLS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TENASCIN;

EID: 84881174013     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2012.0568     Document Type: Article

References (55)

1. Caplan, A.I., and Correa, D. The MSC: An injury drugstore. Cell Stem Cell 9, 11, 2011
2. Singer, N.G., and Caplan, A.I. Mesenchymal stem cells: Mechanisms of inflammation. Annu Rev Pathol 6, 457, 2011
3. Rodrigues, M., Griffith, L., and Wells, A. Adult stem cell survival strategies. In: Ramalingam, M., Ramakrishna, S., and Best, S., eds. Biomaterials and Stem Cells in Regenerative Medicine. Boca Raton, Florida: CRC Press, 2012, pp. 383-405
4. Semont, A., Mouiseddine, M., Francois, A., Demarquay, C., Mathieu, N., Chapel, A., Sache, A., Thierry, D., Laloi, P., and Gourmelon, P. Mesenchymal stem cells improve small intestinal integrity through regulation of endogenous epithelial cell homeostasis. Cell Death Differ 17, 952, 2010
5. van der Bogt, K.E., Schrepfer, S., Yu, J., Sheikh, A.Y., Hoyt, G., Govaert, J.A., Velotta, J.B., Contag, C.H., Robbins, R.C., and Wu, J.C. Comparison of transplantation of adipose tissue- and bone marrow-derived mesenchymal stem cells in the infarcted heart. Transplantation 87, 642, 2009
6. Noort, W.A., Feye, D., Van Den Akker, F., Stecher, D., Chamuleau, S.A., Sluijter, J.P., and Doevendans, P.A. Mesenchymal stromal cells to treat cardiovascular disease: Strategies to improve survival and therapeutic results. Panminerva Med 52, 27, 2010
7. Zimmermann, C.E., Gierloff, M., Hedderich, J., Acil, Y., Wiltfang, J., and Terheyden, H. Survival of transplanted rat bone marrow-derived osteogenic stem cells in vivo. Tissue Eng Part A 17, 1147, 2011
8. Mias, C., Trouche, E., Seguelas, M.H., Calcagno, F., Dignet- George, F., Piercecchi-Marti, M.D., Daniel, L., Bianchi, P., Calise, D., Bourin, P., Parini, A., and Cussac, D. Ex vivo pretreatment with melatonin improves survival, proangiogenic/ mitogenic activity, and efficiency of mesenchymal stem cells injected into ischemic kidney. Stem Cells 26, 1749, 2008
9. Song, H., Cha, M.J., Song, B.W., Kim, I.K., Chang, W., Lim, S., Choi, E.J., Ham, O., Lee, S.Y., Chung, N., Jang, Y., and Hwang, K.C. Reactive oxygen species inhibit adhesion of mesenchymal stem cells implanted into ischemic myocardium via interference of focal adhesion complex. Stem Cells 28, 555, 2008
10. Zhu, W., Chen, J., Cong, X., Hu, S., and Chen, X. Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells 24, 416, 2006
11. Deschepper, M., Oudina, K., David, B., Myrtil, V., Collet, C., Bensidhoum, M., Logeart-Avramoglou, D., and Petite, H. Survival and function of mesenchymal stem cells (MSCs) depend on glucose to overcome exposure to long-term, severe and continuous hypoxia. J Cell Mol Med 15, 1505, 2010
12. Liu, Y., Wang, L., Kikuiri, T., Akiyama, K., Chen, C., Xu, X., Yang, R., Chen, W., Wang, S., and Shi, S. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-gamma and TNF-alpha. Nat Med 17, 1594, 2011
13. Fan, V.H., Tamama, K., Au, A., Littrell, R., Richardson, L.B., Wright, J.W., Wells, A., and Griffith, L.G. Tethered epidermal growth factor provides a survival advantage to mesenchymal stem cells. Stem Cells 25, 1241, 2007
14. Gotherstrom, C., Lundqvist, A., Duprez, I.R., Childs, R., Berg, L., and le Blanc, K. Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. Cytotherapy 13, 269, 2011
15. Rodrigues, M., Turner, O., Stolz, D., Griffith, L.G., and Wells, A. Production of reactive oxygen species by multipotential stromal cells/mesenchymal stem cells on exposure to FasL. Cell Transplant 21, 2171, 2012
16. Yamaza, T., Miura, Y., Bi, Y., Liu, Y., Akiyama, K., Sonoyama, W., Patel, V., Gutkind, S., Young, M., Gronthos, S., Le, A., Wang, C.Y., Chen, W., and Shi, S. Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS One 3, e2615, 2008
17. Crop, M.J., Korevaar, S.S., de Kuiper, R., Ijzermans, J.N., van Besouw, N.M., Baan, C.C., Weimar, W., and Hoogduijn, M.J. Human mesenchymal stem cells are susceptible to lysis by CD8 + T-cells and NK cells. Cell Transplant 20, 1547, 2011
18. Tamama, K., Fan, V.H., Griffith, L.G., Blair, H.C., and Wells, A. Epidermal growth factor as a candidate for ex vivo expansion of bone marrow-derived mesenchymal stem cells. Stem Cells 24, 686, 2006
19. Rodrigues, M., Blair, H., Stockdale, L., Griffith, L., and Wells, A. Surface tethered epidermal growth factor protects proliferating and differentiating multipotential stromal cells from FasL induced apoptosis. Stem Cells 31, 104, 2012
20. Midwood, K.S., and Orend, G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal 3, 287, 2009
21. Udalova, I.A., Ruhmann, M., Thomson, S.J., and Midwood, K.S. Expression and immune function of tenascin-C. Crit Rev Immunol 31, 115, 2011
22. Jones, P.L., and Jones, F.S. Tenascin-C in development and disease: Gene regulation and function. Matrix Biol 19, 581, 2000
23. Engel, J. EGF-like domains in extracellular matrix proteins: Localized signals for growth and differentiatioñ FEBS Lett 251, 1, 1989
24. Swindle, C.S., Tran, K.T., Johnson, T.D., Banerjee, P., Mayes, A.M., Griffith, L., and Wells, A. Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol 154, 459, 2001
25. Iyer, A.K., Tran, K.T., Borysenko, C.W., Cascio, M., Camacho, C.J., Blair, H.C., Bahar, I., and Wells, A. Tenascin cytotactin epidermal growth factor-like repeat binds epidermal growth factor receptor with low affinity. J Cell Physiol 211, 748, 2007
26. Murphy-Ullrich, J.E., Lightner, V.A., Aukhil, I., Yan, Y.Z., Erickson, H.P., and Hook, M. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J Cell Biol 115, 1127, 1991
27. Tamama, K., Kawasaki, H., and Wells, A. Epidermal growth factor (EGF) treatment on multipotential stromal cells (MSCs). Possible enhancement of therapeutic potential of MSC. J Biomed Biotechnol 2010, 795385, 2010
28. Rodrigues, M., Griffith, L., and Wells, A. Growth factor regulation of proliferation and survival of multipotential stromal cells. Stem Cell Res Ther 1, 32, 2010
29. Marcantonio, N.A., Boehm, C.A., Rozic, R.J., Au, A., Wells, A., Muschler, G.F., and Griffith, L.G. The influence of tethered epidermal growth factor on connective tissue progenitor coloy formation. Biomaterials 30, 4629, 2009
30. Yates, C.C., Whaley, D., and Wells, A. Transplanted firbroblasts prvents dysfuncional repair in a murine CXCR3- deficient scarring model. Cell Transplant 21, 919, 2012
31. Krall, J.A., Beyer, E.M., and Macbeath, G. High- and lowaffinity epidermal growth factor receptor-ligand interactions activate distinct signaling pathways. PLoS One 6, 15945, 2011
32. Roepstorff, K., Grandal, M.V., Henriksen, L., Knudsen, S.L., Lerdrup, M., Grovdal, L., Willumsen, B.M., and van Deurs, B. Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic 10, 1115, 2009
33. Tolino, M.A., Block, E.R., and Klarlund, J.K. Brief treatment with heparin-binding EGF-like growth factor, but not with EGF, is sufficient to accelerate epithelial wound healing. Biochim Biophys Acta 1810, 875, 2011
34. Wells, A. EGF receptor. Int J Biochem Cell Biol 31, 637, 1999
35. Wells, A., Welsh, J.B., Lazar, C.S., Wiley, H.S., Gill, G.N., and Rosenfeld, M.G. Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. Science 247, 962-964, 1990
36. Haugh, J.M., Huang, A.C., Wiley, H,S., Wells, A., and Lauffenburger, D.A. Internalized epidermal growth factor receptors participate in the activation of p21(ras) in fibroblasts. J Biol Chem 274, 34350, 1999
37. Haugh, J.M., Schooler, K., Wells, A., Wiley, H.S., and Lauffenburger, D.A. Effect of epidermal growth factor receptor internalization on regulation of the phospholipase C-gamma1 signaling pathway. J Biol Chem 274, 8958, 1999
38. Chen,P.,Xie,H.,andWells,A.MitogenicsignalingfromtheEGF receptor is attenuated by a phospholipase C-gamma/protein kinase C feedbackmechanism.Mol Biol Cell 7, 871, 1996
39. He, Y.Y., Huang, J.L., and Chignell, C.F. Delayed and sustained activation of extracellular signal-regulated kinase in human keratinocytes by UVA: Implications in carcinogenesis. J Biol Chem 279, 53867, 2004
40. Bardeesy, N., Kim, M., Xu, J., Kim, R.S., Shen, Q., Bosenberg, M.W., Wong, W.H., and Chin, L. Role of epidermal growth factor receptor signaling in RAS-driven melanoma. Mol Cell Biol 25, 4176, 2005
41. Block, E.R., Tolino, M.A., Lozano, J.S., Lathrop, K.L., Sullenberger, R.S., Mazie, A.R., and Klarlund, J.K. Free edges in epithelial cell sheets stimulate epidermal growth factor receptor signaling. Mol Biol Cell 21, 2172, 2010
42. Iyer, A.K., Tran, K.T., Griffith, L., and Wells, A. Cell surface restriction of EGFR by a tenascin cytotactin-encoded EGFlike repeat is preferential for motility-related signaling. J Cell Physiol 214, 504, 2008
43. Tran, K.T., Griffith, L., and Wells A. Extracellular matrix signaling through growth factor receptors during wound healing. Wound Repair Regen 12, 262, 2004
44. Chiquet-Ehrismann, R., Kalla, P., Pearson, C.A., Beck, K., and Chiquet, M. Tenascin interferes with fibronectin action. Cell 53, 383, 1988
45. Mackie, E.J., Thesleff, I., and Chiquet-Ehrismann, R. Tenascin is associated with chondrogenic and osteogenic differentiation in vivo and promotes chondrogenesis in vitro. J Cell Biol 105, 2569, 1987
46. Murphy, L.I., Fischer, D., Chiquet-Ehrismann, R., and Mackie, E.J. Tenascin-C induced stimulation of chondrogenesis is dependent on the presence of the C-terminal fibrinogen-like globular domain. FEBS Lett 480, 189, 2000.
47. Jones, P.L., Crack, J., and Rabinovitch, M. Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the alpha v beta 3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J Cell Biol 139, 279, 1997
48. Jang, J.H., and Chung, C.P. Tenascin-C promotes cell survival by activation of Akt in human chondrosarcoma cell. Cancer Lett 229, 101, 2005
49. Garwood, J., Garcion, E., Dobbertin, A., Heck, N., Calco, V., ffrench-Constant, C., and Faissner A. The extracellular matrix glycoprotein Tenascin-C is expressed by oligodendrocyte precursor cells and required for the regulation of maturation rate, survival and responsiveness to platelet-derived growth factor. Eur J Neurosci 20, 2524, 2004
50. Murphy-Ullrich, J.E. The de-adhesive activity of matricellular proteins: Is intermediate cell adhesion an adaptive state? J Clin Invest 107, 785, 2001
51. Midwood, K., Sacre, S., Piccinini, K.M., Inglis, J., Trebaul, A., Chan, E., Drexler, S., Sofat, N., Kashiwagi, N., Orend, G., Brennan, F., and Foxwell, B. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflamamtion in arthritic joint disease. Nat Med 15, 774, 2009
52. Mackie, E.J., and Tucker, R.P. The Tenascin-C knock-out revisited. J Cell Sci 112, 3847, 1999
53. Schultz, G.S., and Wysocki, A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen 17, 153, 2009
54. Yates, C.C., Whaley, D., Kulasekaran, P., Hancock, W.W., Lu, B., Bodnar, R., Newsome, J., Hebda, P.A., and Wells, A. Delayed and deficient dermal maturation in mice lacking the CXCR3 ELR-negative chemokine receptor. Am J Pathol 171, 484, 2007
55. Midwood, K.S., and Shwarzbauer, J.E. Tenascin-C maintains matrix contraction via focal adhesion kinase- and Rhomediated signaling pathways. Mol Biol Cell 13, 3601, 2002.